Banners of Samsung Biologics are displayed for DCAT Week 2024 at a hotel in New York in this undated handout photo released Monday. Courtesy of Samsung Biologics

Samsung Biologics is planning more than 50 meetings with global big pharmaceutical companies at the upcoming DCAT Week 2025 in the United States, seeking to aggressively expand its network, the biotech said Monday.

Originally launched in 1890 by the New York Chamber of Commerce, the annual bio and pharmaceutical networking event, now hosted by the U.S. Drug, Chemical & Associated Technologies Association (DCAT), is scheduled to take place in New York from March 17 to 20.

DCAT Week is widely recognized as an event focused on fostering partnerships between companies, as more than 90 percent of the participants are high-level executives with decision-making authority.

Samsung Biologics CEO John Rim will attend the event. Rim, who has participated in the event since 2023, plans to discuss strategic partnerships with ranking officials in the industry.

The company said it will set up its exclusive meeting room at the event, where it will hold over 50 business meetings with global pharmaceutical companies during its four-day run.

In doing so, Rim will focus on promoting Samsung Biologics' competitiveness as a leading contract development and manufacturing organization (CDMO). He will also lead efforts to sign actual deals and expand the company's client pool.

Samsung Biologics has participated in DCAT Week every year since 2016, except for the 2020 edition, which was canceled due to the COVID-19 pandemic.

On March 20, Samsung Biologics will participate in the annual dinner of DCAT Week 2025 as a sponsor along with other global CDMOs, including Lonza and Thermo Fisher Scientific. The dinner is anticipated to be attended by more than 2,500 industry officials, serving as an important opportunity for networking and business partnerships.